We are a Tucson, Arizona based non-profit organization of accredited investors who seek opportunities to invest in Southwest regional startup or early stage companies.
Present your Company
The DESERT ANGELS ™ welcomes applications from startup or early stage companies. We evaluate applications on an ongoing basis and meet monthly from September through June.
Present your company
Become a member
As a vibrant, growing organization, the DESERT ANGELS ™ welcomes new members. If you are an accredited investor with a tenacious appetite for helping early-stage companies succeed, we’d love to get to know you better at an upcoming dinner meeting.
It is safe to say that there would have been no Calimmune without the early support of the Desert Angels.
Many members of the DA share our passion and see the potential for gene therapy to transform healthcare and liberate patients from chronic and incurable diseases. Their investments have helped us grow this company to what it is today. We truly hope Calimmune’s work will be life-changing for the people we plan to serve and the investors that supported us.
Building on a long-standing commitment to foot comfort, Kentwool, maker of the “World’s Best Sock,” announced today the introduction of a therapeutic sock for foot pain relief. The new SensationWool sock features Kentwool’s signature, superfine Merino wool in combination with Nufabrx® nylon, which is infused with capsaicin and a synthetic cooling agent. This combination of […]
By Ali Parnian – Contributing writer I recently met with Gregg Scoresby, CEO of CampusLogic Inc., at his newly expanded headquarters in Chandler. A high-growth company that wants to “Help Schools Change Lives,” its software is geared toward helping higher education institutions and their students more easily handle student financial services. Read on for Scoresby’s […]
Cancer Prevention Pharmaceuticals, Inc. (CPP), a private biotech company developing novel therapeutics to prevent cancer and other diseases, announced the signing of a license agreement with Mallinckrodt Pharmaceuticals, through its Sucampo AG subsidiary (“Mallinckrodt”), wherein Mallinckrodt obtained exclusive North American commercialization rights to CPP’s lead drug candidate, CPP-1X/sul. In April 2018, UK-based Mallinckrodt had exercised […]